Welcome to our dedicated page for Akero Therapeutics news (Ticker: AKRO), a resource for investors and traders seeking the latest updates and insights on Akero Therapeutics stock.
Akero Therapeutics (NASDAQ: AKRO) is a clinical-stage biotechnology company pioneering FGF21-based therapies for metabolic diseases including NASH and MASH. This page provides investors and researchers with timely updates on clinical developments, regulatory milestones, and corporate announcements directly from the company.
Access authoritative information on Akero's lead candidate efruxifermin (EFX), including Phase 2b/3 trial progress, peer-reviewed research, and strategic partnerships. Our curated news collection covers essential updates, scientific presentations, and financial reports while maintaining strict compliance with financial disclosure standards.
Key content includes trial result analyses, FDA communications, patent developments, and executive commentary. Bookmark this page for streamlined tracking of Akero's progress in addressing liver fibrosis and metabolic dysfunction through innovative Fc-FGF21 fusion protein therapy.
Akero Therapeutics, Inc. appoints Scott Gangloff as Chief Technology Officer. Gangloff brings 30 years of experience in biopharmaceutical development and manufacturing, having led teams through BLAs and product approvals. He will contribute to the commercialization and manufacturing strategy of efruxifermin, a Phase 3 trial drug for MASH treatment.
FAQ
What is the current stock price of Akero Therapeutics (AKRO)?
What is the market cap of Akero Therapeutics (AKRO)?
